Tiffany Rui Xuan Gan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tiffany Rui Xuan Gan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Dean Ho
The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore
3 shared publications Agata Blasiak
The N.1 Institute for Health (N.1), National University of Singapore Singapore Singapore
2 shared publications- Agata Blasiak
The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore
2 shared publications - Anh Thanh Lan Truong
The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore
2 shared publications - Kirthika Senthil Kumar
Department of Biomedical Engineering, National University of Singapore, Singapore 117575, Singapore
2 shared publications - Lester Wen Jeit Tan
The Institute for Digital Medicine (WisDM), National University of Singapore, Singapore, Singapore
2 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 10 (3)
AI‐assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysis
Background: Standard‐of‐care for warfarin dose titration is conventionally based on physician‐guided drug dosing. This may lead to frequent deviations from target international normalized ratio (INR) due to inter‐ and intra‐patient variability and may potentially result in adverse events including recurrent thromboembolism and life‐threatening hemorrhage.Objectives: We aim to employ CURATE.AI, a small‐data, artificial intelligence‐derived platform that has been clinically validated in a range of indications, to optimize and guide warfarin dosing.Patients/methods: A personalized CURATE.AI response profile was generated using warfarin dose (inputs) and corresponding change in INR between two consecutive days (phenotypic outputs) and used to identify and recommend an optimal dose to achieve target treatment outcomes. CURATE.AI's predictive performance was then evaluated with a set of metrics that assessed both technical performance and clinical relevance.Results and conclusions: In this retrospective study of 127 patients, CURATE.AI fared better in terms of Percentage Absolute Prediction Error and Percentage Prediction Error of 20% compared to other models in the literature. It also had negligible underprediction bias, potentially translating into lower bleeding risk. Modeled potential time in therapeutic range with CURATE.AI was not significantly different from physician‐guided dosing, so it is on‐par yet provides a systematic approach to warfarin dosing, easing the mental‐burden on guesswork by physicians.This study lays the groundwork for the prospective study of CURATE.AI as a clinical decision support system. CURATE.AI may facilitate the effective use of affordable warfarin with a well‐established safety profile, without the need for costly, new oral anticoagulants. This can have significant impact both on the individual and public health.
- 3 February 2025
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 10 (3)
Open AccessAI‐assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysis
Background: Standard‐of‐care for warfarin dose titration is conventionally based on physician‐guided drug dosing. This may lead to frequent deviations from target international normalized ratio (INR) due to inter‐ and intra‐patient variability and may potentially result in adverse events including recurrent thromboembolism and life‐threatening hemorrhage.Objectives: We aim to employ CURATE.AI, a small‐data, artificial intelligence‐derived platform that has been clinically validated in a range of indications, to optimize and guide warfarin dosing.Patients/methods: A personalized CURATE.AI response profile was generated using warfarin dose (inputs) and corresponding change in INR between two consecutive days (phenotypic outputs) and used to identify and recommend an optimal dose to achieve target treatment outcomes. CURATE.AI's predictive performance was then evaluated with a set of metrics that assessed both technical performance and clinical relevance.Results and conclusions: In this retrospective study of 127 patients, CURATE.AI fared better in terms of Percentage Absolute Prediction Error and Percentage Prediction Error of 20% compared to other models in the literature. It also had negligible underprediction bias, potentially translating into lower bleeding risk. Modeled potential time in therapeutic range with CURATE.AI was not significantly different from physician‐guided dosing, so it is on‐par yet provides a systematic approach to warfarin dosing, easing the mental‐burden on guesswork by physicians.This study lays the groundwork for the prospective study of CURATE.AI as a clinical decision support system. CURATE.AI may facilitate the effective use of affordable warfarin with a well‐established safety profile, without the need for costly, new oral anticoagulants. This can have significant impact both on the individual and public health.
- 31 December 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (2)
CURATE.AI—Artificial Intelligence‐Derived Personalized Tacrolimus Dosing for Pediatric Liver Transplant: A Retrospective Study
Tacrolimus is the cornerstone of immunosuppressive therapy after pediatric liver transplantation. However, reliance on the physician's experience for dose titration, coupled with tacrolimus's narrow therapeutic window and inter‐ and intrapatient variability, often results in frequent under or overdosing events with detrimental patient outcomes. Existing predictive dose personalization models are not readily feasible for clinical implementation, as they require multiple measurements each day while the standard frequency is once daily. CURATE.AI, a small‐data artificial intelligence‐derived platform, is developed as a clinical decision support system to dynamically personalize doses using the patient's own data obtained once a day. Retrospective dose personalization with CURATE.AI on 16 patients’ data demonstrates potential to enable more patients to reach therapeutic range within the first week. The findings support the testing of CURATE.AI in a prospective controlled trial as an aid for the physician's decision on tacrolimus dose personalization after pediatric liver transplantation.
- 31 December 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (2)
CURATE.AI—Artificial Intelligence‐Derived Personalized Tacrolimus Dosing for Pediatric Liver Transplant: A Retrospective Study
Tacrolimus is the cornerstone of immunosuppressive therapy after pediatric liver transplantation. However, reliance on the physician's experience for dose titration, coupled with tacrolimus's narrow therapeutic window and inter‐ and intrapatient variability, often results in frequent under or overdosing events with detrimental patient outcomes. Existing predictive dose personalization models are not readily feasible for clinical implementation, as they require multiple measurements each day while the standard frequency is once daily. CURATE.AI, a small‐data artificial intelligence‐derived platform, is developed as a clinical decision support system to dynamically personalize doses using the patient's own data obtained once a day. Retrospective dose personalization with CURATE.AI on 16 patients’ data demonstrates potential to enable more patients to reach therapeutic range within the first week. The findings support the testing of CURATE.AI in a prospective controlled trial as an aid for the physician's decision on tacrolimus dose personalization after pediatric liver transplantation.
- Open Access
CURATE.AI – AI-derived personalized tacrolimus dosing for pediatric liver transplant: A retrospective study
Tacrolimus is the cornerstone of immunosuppressive therapy after pediatric liver transplantation. However, reliance on the physician’s experience for dose titration, coupled with tacrolimus’s narrow therapeutic window and inter and intra-patient variability, often results in frequent under or over-dosing with detrimental patient outcomes. Existing predictive dose personalization models are not readily feasible for clinical implementation, as they require multiple measurements each day while the standard frequency is once daily. We developed CURATE.AI, a small-data artificial intelligence-derived platform, as a clinical decision support system to personalize doses using the patient’s own data obtained once a day. Retrospective dose personalization with CURATE.AI on 16 patients’ data demonstrated potential to enable patients to stay in the therapeutic range longer and reach the therapeutic range significantly earlier. Our findings support the testing of CURATE.AI in a prospective controlled trial as an aid for the physician’s decision on tacrolimus dose personalization after pediatric liver transplantation.
Open AccessCURATE.AI – AI-derived personalized tacrolimus dosing for pediatric liver transplant: A retrospective study
Tacrolimus is the cornerstone of immunosuppressive therapy after pediatric liver transplantation. However, reliance on the physician’s experience for dose titration, coupled with tacrolimus’s narrow therapeutic window and inter and intra-patient variability, often results in frequent under or over-dosing with detrimental patient outcomes. Existing predictive dose personalization models are not readily feasible for clinical implementation, as they require multiple measurements each day while the standard frequency is once daily. We developed CURATE.AI, a small-data artificial intelligence-derived platform, as a clinical decision support system to personalize doses using the patient’s own data obtained once a day. Retrospective dose personalization with CURATE.AI on 16 patients’ data demonstrated potential to enable patients to stay in the therapeutic range longer and reach the therapeutic range significantly earlier. Our findings support the testing of CURATE.AI in a prospective controlled trial as an aid for the physician’s decision on tacrolimus dose personalization after pediatric liver transplantation.
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S197
The future of tacrolimus dosing: harnessing the potential of CURATE.AI for tacrolimus dose optimization: retrospective data analysis
Tiffany Gan, Shi-Bei Tan, Kirthika Senthil Kumar, Anh Truong, Lester Tan, Agata Blasiak, Marion Aw, Dean Ho, Vidyadhar Mali. Korean J Transplant 2022;36:197. https://doi.org/10.4285/ATW2022.F-3320
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S197
The future of tacrolimus dosing: harnessing the potential of CURATE.AI for tacrolimus dose optimization: retrospective data analysis
Tiffany Gan, Shi-Bei Tan, Kirthika Senthil Kumar, Anh Truong, Lester Tan, Agata Blasiak, Marion Aw, Dean Ho, Vidyadhar Mali. Korean J Transplant 2022;36:197. https://doi.org/10.4285/ATW2022.F-3320